arrow
N

Natàlia Jiménez

Hospital Clínic de Barcelona
H指数:22
被引数:1,289

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Non-Cancer Causes of Death in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Analysis

转移性激素敏感性前列腺癌患者的非癌性死亡原因:一项真实世界分析

2026-05-010
OAAI
Corrigendum to “Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors” [Eur. Urol. Open Sci. 70 (2024) 86–90]

勘误:“接受雄激素受体通路抑制剂治疗的有转移性激素敏感性前列腺癌患者中RB1、PTEN和TP53基因的预后表达特征”[Eur. Urol. Open Sci. 70 (2024) 86–90]

2025-06-040
OA
Corrigendum to “Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients” [Eur. Urol. Oncol. 7 (2024) 954–964]

勘误:关于“基于RB1、PTEN和TP53在转移性激素敏感性前列腺癌患者中开发并独立验证预后基因表达签名”[Eur. Urol. Oncol. 7 (2024) 954–964]

2025-05-010
PRE
Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors

雄激素受体途径抑制剂治疗的转移性激素敏感型前列腺癌患者RB1、PTEN和TP53基因的预后表达特征

2024-12-011
PRE
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients
2024-08-014
OA
SELNET clinical practice guidelines for bone sarcoma
2022-06-0120
OAAI
TMPRSS2-ERG expression and clinical evolution of metastatic hormone sensitive prostate cancer
2021-09-010
OAAI
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment
2021-06-0124
OAAI
Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
2020-11-0211
OAAI
Neuroendocrine (NE) expression profiling in non-castrate tumours is associated with poor therapy benefit and adverse clinical outcome in metastatic castration-resistant prostate cancer (mCRPC) patients
2020-09-010
OAAI
Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer
CELLS
IF5.2
2020-01-1417
OAAI
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer
2019-03-2320
OAAI
TMPRSS2-ERG predictive value for taxanes resistance according to prior second-line hormonal manipulations in metastatic castration resistant prostate cancer
2017-07-010
PRE